The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis

Kristin Mickle, Karen E. Lasser, Jeffrey S Hoch, Lauren E. Cipriano, William B. Dreitlein, Steven D. Pearson

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.

Original languageEnglish (US)
Pages (from-to)10-15
Number of pages6
JournalJournal of managed care & specialty pharmacy
Issue number1
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy


Dive into the research topics of 'The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis'. Together they form a unique fingerprint.

Cite this